The value of LncRNA SNHG5 as a marker for the diagnosis and prognosis of gastric cancer

摘要

Objective: To elucidate the value of serum lncRNA SNHG5 as a marker for the diagnosis and prognosis in gastric cancer. Methods: From January 2017 to January 2018, serum samples were collected from 50 cases of gastric cancer patients and 50 cases of benign gastrosia who underwent operations in our hospital, and 50 cases of healthy person. We detected the expression level of serum lncRNA SNHG5 in all research targets and the expression levels of LncRNA SNHG5 in the cancer adjacent tissues and cancer tissues of gastric cancer patients to analyze the relationship between serum LncRNA SNHG5 level and clinicopathological parameters. ROC curve was used to analyze its prognostic value of patients with gastric cancer, while Cox regression model was used to analyze the survival predictors of short-term adverse events. Results: The expression of lncRNA SNHG5 in the serum of gastric cancer was down-regulated, lower than that in the benign gastrosia group and healthy group ( P 0.05). The relative expression of lncRNA SNHG5 in cancer tissues was down-regulated compared with that in adjacent tissues ( P 0.05). lncRNA SNHG5 was correlated with drinking history and TNM stage ( P 0.05). The difference of serum lncRNA SNHG5 15 days and 1 month after operation was significant ( P 3 = 0.0001, P 4 = 0.0135). The relative expression of serum lncRNA SNHG5 in the death group was noticeably lower than that in the survival group (P 0.05). lncRNA SNHG5 is a survival predictor of short-term adverse events in patients with gastric cancer. Conclusion: The expression of lncRNA SNHG5 in gastric cancer patients before operation and those with poor prognosis decreased. Therefore, it is of high diagnostic value in prognosis prediction and is expected to become a new molecular marker for early diagnosis of gastric cancer.